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expression of phosphorylated (activated) STAT3 in diffuse large B-cell lymphoma (DLBCL) and
the impact of phosphorylated STAT3 (pSTAT3) on prognosis are limited.
Experimental Design—We evaluated expression of pSTAT3 in de novo DLBCL using
immunohistochemistry, gene expression profiling and gene set enrichment analysis. Results are
analyzed in correlation with cell-of-origin, critical lymphoma biomarkers and genetic
translocations.
Results—pSTAT3 expression was observed in 16% of DLBCL and was associated with
advanced stage, multiple extranodal sites of involvement, activated B-cell-like (ABC) subtype,
MYC expression and MYC/BCL2 expression. Expression of pSTAT3 predicted inferior overall
survival (OS) and progression-free survival (PFS) in de novo DLBCL patients. When DLBCL
cases were stratified according to cell-of-origin or MYC expression, pSTAT3 expression did not
predict inferior outcome, respectively. Multivariate analysis showed that the prognostic
predictability of pSTAT3 expression was due to its association with the ABC subtype, MYC
expression and adverse clinical features. Gene expression profiling demonstrated up-regulation of
genes, which can potentiate function of STAT3. Gene set enrichment analysis showed the JAK-
STAT pathway to be enriched in pSTAT3+ DLBCL.
Conclusions—The results of this study provide a rationale for the ongoing successful clinical
trials targeting the JAK-STAT pathway in DLBCL.
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INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma and
encompasses a heterogeneous group of tumors with several variants, subgroups and
subtypes or entities (1). With the current standard treatment of rituximab,
cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), 5-year overall
survival for all patients with DLBCL ranges from 30 to 50% (2). Gene expression profiling
(GEP) has identified distinct molecular subtypes, in particular the germinal center B-cell-
like (GCB) and activated B-cell-like (ABC) DLBCL (3). The introduction of rituximab in
the past decade has improved the survival of DLBCL patients (4), but patients with ABC-
like DLBCL still display a worse outcome (5).
STAT3 is a member of the signal transducer and activator of transcription (STAT) family of
transcription factors. In unstimulated cells, STAT3 is inactive and located in the cytoplasm.
STAT3 is usually activated by growth factors and cytokines, such as IL-6 or IL-10 (6, 7).
Activation of STAT3 is mediated by phosphorylation of a tyrosine residue (Tyr 705), which
induces STAT3 dimerization and translocation to the nucleus (8). STAT3 transcriptional
activity and DNA binding can be further modified by phosphorylation of Ser 727 (9) or
p300-mediated acetylation at Lys 685 (10). Activated STAT3 regulates tumor growth,
invasion, cell proliferation, angiogenesis, immune response and survival (11, 12).
Constitutive activation of STAT3 has been shown in several solid tumors, including
melanoma (13) and carcinomas of the lung (14), breast (15), ovary (16), colon (17), and
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prostate (18), while STAT3 mutation is not a frequent event in cancers with the exception of
T-cell large granular lymphocytic leukemia (19).
Both in vitro and in vivo studies have shown that STAT3 is found to be preferentially
activated in the ABC DLBCL (20, 21). In some earlier studies with a limited number of
DLBCL patients treated with R-CHOP (22) or epratuzumab/R-CHOP (23), pSTAT3
expression did not show significant survival differences. However, in a very recent cohort
study of DLBCL patients treated with R-CHOP, pSTAT3 expression predicted poorer
outcome (24). In the present study, we evaluated the prevalence of pSTAT3 expression, its




A cohort of 443 patients with de novo DLBCL treated with the standard R-CHOP regimen
was collected as part of The International DLBCL Rituximab-CHOP Consortium Program
Study (25). All cases were centrally reviewed by a group of hematopathologists and
classified according to the World Health Organization classification criteria (1). Cases that
were excluded from this study included: large cell transformation of low-grade B-cell
lymphoma, immunodeficiency-associated lymphoproliferative disorders (especially human
immunodeficiency virus infection), primary mediastinal large B-cell lymphoma, primary
cutaneous B-cell lymphoma, and primary central nervous system DLBCL. All patients had
sufficient clinical and follow-up data. The present study was conducted in accord with the
Declaration of Helsinki. Utilization of archived diagnostic tissue samples and therapy and
outcome data procurement was approved by the Institutional Review Boards (IRBs) of all
participating collaborative institutions. The overall study was approved by the IRB at The
University of Texas MD Anderson Cancer Center in Houston, Texas, USA.
Tissue microarray immunohistochemical studies
Representative areas with the highest percentage of tumor cells were selected for tissue
microarray (TMA) construction as described previously (5). Immunohistochemical (IHC)
studies for various markers were performed; B-cell lymphoma 2 (BCL2), B-cell lymphoma
6 (BCL6), cyclin D1, CD10, CD30, Forkhead box protein P1 (FOXP1), Germinal Center B
cell-expressed Transcript-1 (GCET1), Multiple Myeloma Oncogene 1 (MUM1), MYC,
Nuclear factor-κB (NF-κB) components (p50, p52, p65, and c-Rel), p53, phosphorylated
protein kinase B (pAKT), and phosphorylated signal transducer and activator of
transcription 3 (pSTAT3). Receiver-operating characteristic (ROC) curves and X-tile
analyses were utilized to assess a cutoff (5). When an optimal cutoff could not be
determined by ROC curve and X-tile analyses, a conventional cutoff value for individual
markers was decided based on previous reports in the literature. The cutoff scores for these
markers were as follows: 10% for cyclin D1; 20% for CD30 and p53; 30% for CD10, and
BCL6, 40% for MYC; 50% for pSTAT3; 60% for GCET1, MUM1 and FOXP1; and 70%
for AKT and BCL2. All markers except cyclin D1 were determined by ROC curve. Any
nuclear expression of each NF-κB component was considered positive.
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Fluorescence in situ hybridization and TP53 sequencing
Fluorescence in situ hybridization (FISH) analysis was performed on formalin-fixed,
paraffin-embedded tissue sections using BCL2 and BCL6 dual-color break-apart probes
(Vysis, Downers Grove, IL), locus-specific IGH/MYC/CEP8 tricolor dual-fusion probes
(Vysis, Downers Grove, IL) and a locus-specific MYC dual-color break-apart probe (Vysis,
Downers Grove, IL) as reported (26). TP53 exon sequencing was performed as described
previously (27). Sequencing data was compared with the TP53 reference sequence
(NC_000017.10) in the Genbank database for data analysis.
Gene expression profiling and gene set enrichment analysis
Total RNA was extracted from formalin-fixed, paraffin-embedded tissue samples using the
HighPure RNA Extraction Kit (Roche Applied Science, Indianapolis, IN) and subjected to
gene expression profiling (GEP) as described previously (5). The robust multi-array analysis
(RMA) algorithm was used for background correction (28), and then quantile normalization
was conducted (29). Cell of origin (COO) classification was determined primarily based on
GEP data and secondarily on immunohistochemical results using the Visco-Young
algorithm as described previously (5).
Gene set enrichment analysis was performed with GSEA application (Broad Institute at
MIT, Cambridge, MA) using Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway
gene sets (186 gene sets). GSEA results with false discovery rate (FDR) ≤ 0.3 were
considered to be significant.
Statistical analysis
Comparison among categorical variables and numerical variables were carried out by using
the Fisher’s exact test and Kruskal-Wallis test, respectively. OS and PFS were defined from
the date of diagnosis to the date of last follow-up or death and from the date of diagnosis to
the date of progression or death, respectively. Survival probability was determined using the
Kaplan-Meier method, with difference compared by the log-rank test. A Cox proportional-
hazards model was used for univariate and multivariate analysis. All variables with P<0.05
were considered to be statistically significant. SPSS Statistics V21 (IBM, Chicago, IL),
GraphPad Prism V5 (GraphPad software, La Jolla, CA) and X-Tile version 3.6.1 (Yale
University, New Haven, CT) were used for statistical analyses.
RESULTS
pSTAT3 expression is associated with poor outcome
The clinical features of the patient cohort are similar to that of our prior studies (30).
Nuclear expression with or without cytoplasmic expression of pSTAT3 in large atypical
lymphoid cells was regarded as positive in association with intensity (Figure S1). Expression
of pSTAT3 in small, mature lymphocytes was disregarded. Clinical characteristics of
patients with pSTAT3+ versus pSTAT3− DLBCL are summarized in Table 1. pSTAT3 was
positive in 72 (16%) patients of which 49 were men and 23 women. pSTAT3+ DLBCL did
not show distinct morphologic features compared to pSTAT3− DLBCL, having
predominantly centroblastic morphology. Advanced stage (66% vs. 52%, p=0.036),
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involvement of multiple extranodal sites (33% vs. 20%, p=0.026) and the ABC subtype
(67% vs. 45%, p=0.001) were more commonly observed in pSTAT3+ DLBCL compared
with pSTAT3− DLBCL. Significant differences with respect to pSTAT3 expression were
not observed for gender, age, B symptoms, ECOG score, serum LDH, IPI, tumor size and
treatment response (p>0.05).
Patients with pSTAT3+ DLBCL had significantly worse OS and PFS compared with
patients with pSTAT3− DLBCL (Figure 1-A and B). The 5-year OS was 48.8% for
pSTAT3+ DLBCL and 64.7% for pSTAT3− DLBCL patients (p=0.014). The 5-year PFS
was 39.9% for pSTAT3+ DLBCL and 56.2% for pSTAT3− DLBCL patients (p=0.016). The
median OS was 56.9 months (95% CI, 18.1–95.7) for patients with pSTAT3+ DLBCL and
was not reached for pSTAT3− DLBCL patients. The median PFS were 43.5 months (95%
CI, 21.1–65.8) for pSTAT3+ DLBCL and 78.7 months (95% CI, 61.9–95.5) for pSTAT3−
DLBCL patients.
When stratified into GCB and ABC subtypes, patients with pSTAT3+ DLBCL showed a
trend suggestive of inferior OS compared with pSTAT3− DLBCL patients in the GCB
subgroup (p=0.189) and the ABC subgroup (p=0.089), respectively (Figure 1-C and E).
Patients with pSTAT3+ DLBCL had worse PFS in the GCB subgroup (p=0.044), but only
showed a trend in the ABC subgroup (p=0.325) (Figure 1-D and F). Separating stage I–II vs.
III–IV, pSTAT3 retained prognostic value in the lower stage subgroup (p=0.008 for OS and
p=0.021 for PFS), but not in the advanced stage subgroup (p=0.591 for OS and p=0.441 for
PFS). In the patient subgroup with < 2 extranodal sites of involvement, pSTAT3 predicted
poorer prognosis (p=0.029 for OS and p=0.028 for PFS), but not in patients with ≥ 2
extranodal sites (p=0.958 for OS and p=0.881 for PFS).
We also measured STAT3 mRNA levels and evaluated if STAT3 mRNA level correlated
with pSTAT3 expression. To measure mRNA expression of the STAT3 gene, from the GEP
dataset, we retrieved the intensity of four STAT3 probe-sets and used the average value as
STAT3 expression at the mRNA level. Patients were divided into 3 groups for survival
analysis according to the mean values of mRNA expression: low STAT3 mRNA (< mean –
one standard deviation), high STAT3 mRNA (> mean + one standard deviation), and
intermediate STAT3 mRNA levels (the remaining cases). The mean values of pSTAT3
expression in cases with low, intermediate and high STAT3 mRNA were 12%, 22% and
36%, respectively, showing correlation between STAT3 mRNA and pSTAT3 expression
(p=0.0002) (Figure S2). However, STAT3 mRNA did not show significant difference with
respect to OS in all cases (p=0.1487) and ABC DLBCL (p=0.6183). Although significant
stratification was seen in GCB DLBCL, cases with high STAT3 mRNA and low mRNA
showed the best and worst survival, respectively. Seven cases with high STAT3 mRNA in
GCB DLBCL is insufficient number to achieve statistical power and could be an random
event. The worse prognosis in cases with low STAT3 mRNA could be due to contamination
from background inflammatory cells.
pSTAT3 expression is associated with MYC and MYC/BCL2 expression
Immunohistochemical and genetic characteristics of pSTAT3+ and pSTAT3− DLBCL are
summarized in Table 2. An association between STAT3 and the MYC and BCL2 genes has
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been reported previously by other investigators in limited patient series (31, 32). Therefore,
in this study we comprehensively assessed MYC and BCL2 expression with respect to
pSTAT3, in association with genetic aberrations. MYC and MYC/BCL2 double expression
were more commonly observed in pSTAT3+ DLBCL cases (p<0.001 and p=0.001,
respectively). However, BCL2 expression was not significantly different in DLBCL cases
positive or negative for pSTAT3 expression (p=0.420). Rearrangements of BCL2, BCL6 or
MYC detected by FISH did not show any significant differences between pSTAT3+ DLBCL
and pSTAT3− DLBCL (p>0.05). One pSTAT3+ case (2%) showed rearrangements of both
MYC and BCL6 genes and no case had coexistent MYC and BCL2 rearrangements.
Regarding TP53 exon mutations detected by sequencing, TP53 gene deletions detected by
FISH, or p53 expression, there were no significant differences between pSTAT3+ and
pSTAT3− DLBCL cases (p>0.05). Stratifying our cohort according to p53 expression,
pSTAT3+ DLBCL showed a significant worse outcome in OS (p=0.016) and PFS (p=0.024)
in the p53 negative group (Figure 2-A and B). A total of 13 (19%) DLBCLs harbored TP53
mutations. All of the TP53 mutations were confined to exons 4 to 8, which are the most
critical sites for DNA binding (33). Eleven cases were missense mutations and 2 cases were
nonsense mutations.
Association of pSTAT3 expression with NF-kB components, cyclin D1 or pAKT
Cooperation of STAT3 and NF-κB is well known (21, 34). However, few studies have
correlated expression of individual NF-κB components (p50, p52, p65 and cRel) with
pSTAT3 expression. In this study, a significant trend that p52 single component and
p52/p65 dimer were more commonly observed in pSTAT3+ DLBCL compared to pSTAT3−
DLBCL (p=0.05 and p=0.081, respectively). Other NF-κB single components or
combinations of NF-κB dimers (p50/p65, p50/cRel, and p52/cRel) were not more commonly
expressed in pSTAT3+ DLBCL (p>0.05). Neither the classical NF-κB pathway (p50/p65 or
p50/cRel), nor the alternative NF-κB pathway (p52/p65 or p52/cRel), nor both showed
significant association with pSTAT3 expression (p>0.05).
Cyclin D1 is a known downstream target of pSTAT3 (35) and protein kinase B (AKT) can
be activated via the JAK/STAT pathway (36). Therefore we assessed protein expression of
cyclin D1 and pAKT in this study. Neither cyclin D1 nor pAKT protein expression was
significantly different between pSTAT3+ DLBCL and pSTAT3− DLBCL (p>0.05).
Multivariate Analysis of Prognostic Parameters
Stratified according to MYC expression, the prognostic effect of pSTAT3 was abrogated in
patients with MYC+ DLBCL (p=0.966 for OS and p=0.818 for PFS) (Figure 2-C and D).
Survival analysis was not performed in MYC- group because only 4 MYC-/pSTAT3+ cases
were present. Stratifying DLBCL cases into MYC/BCL2 protein double positive (DP) and
non-double positive (non-DP) groups, pSTAT3 showed no effect on survival in the DP
(p=0.745 for OS and p=0.592 for PFS) as well as the non-DP patient subgroups (p=0.388 for
OS and p=0.281 for PFS) (Figure 2-E, F, G and H). When stratifying DP and non-DP
subgroups into COO classification, no effect on survival was seen (Figure S3 and Table S1).
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Univariate analysis identified advanced age, multiple extranodal sites of involvement, ABC
subtype, pSTAT3 expression and MYC expression increased hazard in patients with de novo
DLBCL (P<0.05 in all variables). Multivariate analysis using these 5 variables demonstrated
that pSTAT3 is not an independent variable (p=0.460 for OS and p=0.523 for PFS). All the
other variables were significant (Table 3).
GEP and GSEA of pSTAT3+ DLBCL
To further characterize pSTAT3+ DLBCL, we compared the GEP signatures of pSTAT3+
and pSTAT3− DLBCL using the Affymetrix HGU133plus2 platform (Affymetrix, Santa
Clara, CA, USA) (Figure 3A). With a false discovery rate (FDR) threshold of 0.3, a total of
26 genes were differentially expressed between the two groups including 15 up-regulated
genes and 11 down-regulated genes in pSTAT3+ DLBCL. Among the up-regulated genes in
pSTAT3+ DLBCL, STAT3, IL2RA, CD44, EPHA4, and CDK5R1 were significant.
Upregulation of the IL2RA gene suggests a positive feedback mechanism of pSTAT3
because IL-2 activates STAT3 via activating Janus kinase (JAK). CD44 can acetylate and
dimerize STAT3 in a growth factor- and cytokine-independent manner and has been shown
to be involved in cell migration, tumor invasion and metastasis, potentiating STAT3
function and partially explaining the adverse outcome in pSTAT3+ DLBCL (37). EPHA4
encodes ephrin receptor A4, which has receptor tyrosine kinase activity. CDK5R1 encodes
CDK5/p35, which is a downstream target molecule of ephrin receptor A4 and it expression
has been shown to predict inferior survival in patients with non-small cell lung cancer (38).
Many of the down-regulated genes encode proteins of unknown function. Huang et al
proposed a prognostically valuable 11-gene signature in PY-STAT3+ DLBCLs (24). The 11
genes were HSD17B4, MT1X, NAT8L, PCNX, RHEB, RNF149, SLA, SLC2A13, ZNF805,
C15orf29 and ZNF420. However, few of these genes (RHEB, PCNX and ZNF420) were
expressed with marginal significance for survival in our cohort and combination of the 11-
genes showed overall significant trend (p=0.07). GSEA analysis showed trends for several
gene sets, including the JAK-STAT pathway gene set, being enriched in pSTAT3+
DLCBCL (Figure 3-B).
DISCUSSION
In the present study, 16% of de novo DLBCL cases expressed pSTAT3. The prevalence of
pSTAT3 expression in DLBCL is lower than that reported in earlier studies in which 30–
40% of DLBCL expressed pSTAT3 (22, 24, 39, 40). Of note, pSTAT3 expression are 67%,
51%, 34%, 23%, 16%, and 11% if the pSTAT3 cutoffs are 10%, 20%, 30%, 40%, 50% and
60%, respectively (Table S2). With 30% cutoff, the prevalence of pSTAT3 expression is in
similar range to prior data. However, our cutoff value for pSTAT3 was determined based on
a ROC curve to achieve optimal sensitivity and specificity. Compared to survival analysis
using 50% cutoff (Figure 1), 30% cutoff does not show any significant differences between
pSTAT3+ DLBCL and pSTAT3− DLBCL (Figure S4). Furthermore, no clinical differences
are observed between the two groups using 30% cutoff except COO classification (Table
S3). We additionally conducted survival analysis in 4 separate quartile groups (Q1: <30%,
Q2: ≥30% and <50%, Q3: ≥50% and <70%, and Q4: ≥70%, Table S4). Although overall
quartile analysis showed significant stratification, Q3 and Q4 did not show significant
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difference (Figure S5, lower row). Merging Q3 and Q4, we conducted survival analysis in 3
groups (T1: <30%, T2: ≥30% and <50%, T3: ≥50%, Table S5). T2 and T3 showed
significant difference, whereas T1 and T2 did not (Figure S5, upper row). Based on our
analysis, we chosed 50% as an optimal cutoff for pSTAT3 expression. With 50% cutoff, we
could minimize possible contamination of pSTAT3 expression in non-lymphoma cells. As
has also been shown by others (22–24, 39), pSTAT3 was more commonly expressed in
ABC-DLBCL. Such a finding can be explained by Ding et al who showed STAT3 gene
transcription was negatively regulated by BCL6, hence providing a basis for STAT3
activation in ABC-DLBCL (20). We also showed that STAT3 mRNA level is quantitatively
correlated with pSTAT3 expression. (Figure S2)
We showed that pSTAT3 expression in de novo DLBCL is associated with adverse
outcome, confirming a similar observation by Huang et al and Meier et al (24, 40). We could
not, however, show that pSTAT3 expression is an independent prognostic factor in DLBCL
patients in multivariate analysis (Table 3). Furthermore, pSTAT3 expression is associated
with MYC expression and MYC/BCL2 double expression. However, when MYC expression
was controlled, pSTAT3 did not significantly predict prognosis (Figure 2). In cases with
MYC/BCL2 DP or non-DP, significant difference was not observed, either. No survival
difference was seen after stratified into GCB/ABC in DP and non-DP groups (Figure S4).
Furthermore, multivariate analysis did not identify pSTAT3 as an independent hazard.
Instead, other variables, such as stage, cell-of-origin classification and MYC expression,
were shown to be independent prognosticators (Table 3). We additionally conducted
bivariate analyses including each variable in the multivariate analysis and pSTAT3
expression to see if increased hazardous effect of pSTAT3 is observed (Table S6). pSTAT3
did not show increased hazard except when pSTAT3 co-analyzed with ABC phenotype.
Therefore, inferior outcome of patients with pSTAT3+ DLBCL appeared to be a result of
the associated poor prognostic indicators such as advanced stage disease and multiple
extranodal sites of involvement. Interestingly, in patients with less aggressive or advanced
disease such as limited stage (stage I or II), involvement of < 2 extranodal sites, absence of
p53 expression, or GCB-type DLBCL, pSTAT3 expression showed a worse outcome. Our
data therefore suggest that pSTAT3 expression predicts poor outcome in less aggressive/
advanced DLBCL, but it does not provide additional survival impact in patients with
advanced disease or with already known poor prognostic factors including MYC expression
or BCL2/MYC co-expression (23, 30, 41).
The results of GEP analysis in this study showed that pSTAT3+ DLBCL is distinct from
pSTAT3− DLBCL. Many of the up-regulated genes, such as STAT3, IL2RA, IL1B, EPHA4,
and CDK5R1 in pSTAT3+ DLBCL contain several binding sites for STAT3 in their
promoters and some of the up-regulated genes have been reported to correlate with
aggressive features in carcinomas (37, 38). The results of GSEA also provide evidence that
the JAK-STAT pathway is enriched in pSTAT3+ DLBCL, although the statistical
significance is marginal. In a recent study by Huang et al (24), the authors suggested that an
11-gene signature was associated with poor OS in patients with STAT3+ DLBCL, treated
with CHOP and R-CHOP, respectively, without achieving statistical significance. Some of
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these genes were marginally up-regulated in pSTAT3+ DLBCL by GEP in our study,
partially in agreement with Huang et al (24).
Although our GEP results did not show that MYC was significantly up-regulated in
pSTAT3+ DLBCL, it is not surprising to observe the correlation between MYC expression
and pSTAT3 in this study because MYC is a known target of STAT3 (31, 42, 43). Kikuchi et
al demonstrated that STAT3 was essential for MYC mRNA expression in a proB cell line
(BAF/B03) (31). Barre et al showed that STAT3 was recruited to the MYC promoters upon
IL-6 stimulation of glioblastoma cells using chromatin immunoprecipitation (ChIP) (42).
Bowman et al reported that MYC expression was induced by STAT3 in fibroblasts (43). In
primary DLBCL patient samples, Gupta et al showed a trend between pSTAT3 and MYC
expression in a small study of 23 patients (23).
NF-κB and pSTAT3 are known to cooperate and four different modes of reciprocal
interaction in transcriptional control have been suggested (34). 1) STAT3/p65 in the nucleus
can recruit p300 histone acetyltransferase, which acetylates histone as well as p65.
Acetylated p65 is less prone to nuclear export, hence persists longer in the nucleus where it
is transcriptionally active. 2) In the nucleus, NF-κB/STAT3 can bind to particular DNA
target sequences at sites where neither can bind alone. 3) Unphosphorylated STAT3 can
bind with and displace IκB so that NF-κB can be activated without any upstream signals. 4)
I-κBζ, which is induced by NF-κB, can bind to STAT3 and inhibit STAT3− DNA binding.
We showed a significant trend that p52 single expression and p52/p65 dimer expression was
more commonly seen in pSTAT3+ DLBCL, supporting a crosstalk between STAT3 and NF-
κB (44, 45). Lam et al showed the induction of IL-6 and IL-10 by NF-κB pathway in ABC
DLBCL cell lines (21). Considering constitutive activation of NF-κB and common pSTAT3
expression in ABC DLBCL, targeting either or both of them appears to be an attractive
addition to the current R-CHOP regimen especially in this subtype.
Recently, STAT3 was found to be a substrate of histone deacetylase 3 (HDAC3) in ABC-
DLBCL (46). Although the primary substrates of HDACs are histones, non-histone proteins
including NF-κB transcription factors also could be targeted by HDACs (47). In the context
of crosstalk between NF-κB and STAT3, targeting HDAC seems to be a reasonable
approach. Gupta et al demonstrated that a HDAC inhibitor panobinostat (also known as
LBH589) could dephosphorylate STAT3 in an ABC-DLBCL cell line, (Ly3), as well as
DLBCL patient samples, in a dose-dependent manner (46). However, a recent phase I study
using panobinostat with everolimus in patients with relapsed and refractory lymphoma did
not show a response in patients with DLBCL (48). Lam et al also showed that blocking
JAK/STAT3 activation using a JAK inhibitor in ABC-DLBCL cell lines reduces cell
proliferation and survival (21). They also demonstrated a synergistic effect on tumor cell
death by combining JAK/STAT3 and NF-κB inactivation in ABC-DLBCL cell lines. A
phase II clinical trial using an oral JAK inhibitor (INCB18424) is in progress in patients
with relapsed or refractory DLBCL or peripheral T-cell lymphoma (NCT01431209).
Scuto et al demonstrated that inhibition of STAT3 with short hairpin RNA was associated
with apoptosis in a human ABC-like DLBCL cell line (Ly3), as well as tumor regression in
NOD-SCID (nonobese diabetic/severe combined immunodeficient) mice injected by Ly3
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cells (49). In their study, direct STAT3 inhibition induced significant reduction of STAT3
targets such as MYC and survivin at the protein level. Survivin is an anti-apoptotic protein
and has been shown to be unfavorable prognostic marker in DLBCL (50). Furthermore,
Scuto et al also showed that inhibition of STAT3 thwarted IL-10-dependent STAT3
activation, proving that STAT3 can be an attractive therapeutic target. Currently, a multi-
institution phase I/II clinical trial using an antisense oligonucleotide inhibitor targeting
STAT3 in DLBCL patients is in progress (NCT01563302).
In summary, pSTAT3 expression is more commonly seen in ABC-DLBCL and is associated
with advanced stage, multiple extranodal sites of involvement, MYC expression and MYC/
BCL2 double expression. Although pSTAT3 is not an independent prognostic marker,
pSTAT3 expression in DLBCL predicts an unfavorable outcome. Gene expression profiling
suggests that pSTAT3+ DLBCL is molecularly distinct from pSTAT3− DLBCL with a
unique oncogenic pathway activation signature, which identify a group of patients with who
might benefit from the use of molecularly targeted therapies. Ongoing successful clinical
trials targeting the STAT3 pathway may shed new light on the significance of STAT3
expression, particularly in refractory/resistant DLBCL.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Activated signal transducer and activator of transcription 3 (STAT3) plays a role in
tumor invasion, cell proliferation, angiogenesis and immune response. Enhanced STAT3
activity has been found in many cancers, but its role in diffuse large B-cell lymphoma
(DLBCL) has not been heavily studied. In this study, we showed that expression of
phosphorylated STAT3 (pSTAT3) was seen in 16% of de novo DLBCL and was
associated advanced stage, multiple extranodal sites of involvement, activated B-cell-like
(ABC) subtype, MYC expression and MYC/BCL2 expression. Although multivariate
analysis did not show expression of pSTAT3 was an independent prognostic marker, the
expression of pSTAT3 showed inferior overall survival and progression-free survival in
de novo DLBCL patients treated with R-CHOP. pSTAT3+ DLBCL up-regulates genes
potentiating function of STAT3, that has been found to be an attractive therapeutic
targets.
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Survival impact of pSTAT3 in de novo DLBCL. A and B. Overall, pSTAT3 showed inferior
overall survival (OS) and progression-free survival (PFS). C and D. In the germinal center
B-cell-like (GCB) subtype, significant survival difference is only seen in PFS (p=0.044). E
and F. In the activated B-cell-like (ABC) subtype, significant survival difference is not seen
in either OS or PFS.
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Survival impact of pSTAT3 in subsets of de novo DLBCL. A and B. In group of DLBCL
without p53 expression by immunohistochemistry, pSTAT3 expression shows adverse effect
in OS and PFS. C and D. In the group of MYC expression, pSTAT3 expression does not
show different outcome in OS and PFS. E and F. In the group of MYC/BCL2 double protein
expression (DP), pSTAT3 expression does not have prognostic impact. G and H. In the
group without MYC/BCL2 double expression (non-DP), pSTAT3 expression does not show
differences in OS and PFS..
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Gene expression profiling and gene set enrichment analysis. A. Gene expression profiling
shows that pSTAT3+ DLBCL is genetically distinct from pSTAT3− DLBCL.
Representative up-regulated and down-regulated genes in the pSTAT3+ DLBCL are
illustrated at the upper end and lower end, respectively. B. Gene set enrichment analysis
shows a trend that KEGG JAK-STAT pathway is enriched in the pSTAT3+ DLBCL.
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Table 1
Clinical characteristics of 443 cases of de novo DLBCL with regard to phosphorylated STAT3 expression
pSTAT3+ pSTAT3−
N (%) N (%) P value
Patients 72 (16) 371 (84)
Gender
  Male 49 (68) 211 (57)
  Female 23 (32) 160 (43) 0.089
Age
  <60 26 (36) 159 (43) 0.300
  ≥60 46 (64) 212 (57)
B symptoms
  Absent 39 (60) 223 (68) 0.252
  Present 26 (40) 107 (32)
ECOG
  <2 53 (83) 267 (85) 0.706
  ≥2 11 (17) 48 (15)
Stage
  I/II 24 (34) 172 (48) 0.036
  III/IV 46 (66) 185 (52)
Extranodal site
  <2 47 (67) 283 (80) 0.026
  ≥2 23 (33) 70 (20)
LDH
  Normal 25 (37) 116 (35) 0.780
  Elevated 42 (63) 216 (65)
IPI
  0–2 32 (44) 210 (58) 0.051
  3–5 40 (56) 154 (42)
Tumor size, cm
  <6 34 (63) 194 (68) 0.529
  ≥6 20 (37) 92 (32)
Treatment response
  CR/PR 63 (88) 332 (90) 0.678
  No response 9 (12) 39 (10)
COO classification
  GCB 24 (33) 204 (55) 0.001
  ABC 48 (67) 166 (45)
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*
pSTAT3, phosphorylated STAT3; OS, overall survival; PFS, progression-free survival; ECOG, Eastern Cooperative Oncology Group; LDH,
lactic dehydrogenase; IPI, International Prognostic Index; CR, complete remission; PR, partial remission; COO, cell-of-origin; GCB, germinal
center B-cell-like; ABC, activated B-cell-like
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Table 2
Immunophenotypic and genetic characteristics of 433 cases of de novo DLBCL with regard to phosphorylated
STAT3 expression
Overall (%) pSTAT3+ (%) pSTAT3− (%) P value
MYC expression 260/398 (65) 61/65 (94) 199/333 (60) <0.001
BCL2 expression 192/398 (48) 35/66 (53) 157/332(47) 0.420
MYC/BCL2 co-expression 130/396 (33) 34/65 (52) 96/331 (29) 0.001
BCL2 rearranged 69/378 (18) 7/59 (12) 62/319 (19) 0.201
BCL6 rearranged 107/321 (33) 20/50 (40) 87/271 (32) 0.327
MYC rearranged 35/382 (9) 4/62 (6) 31/320 (10) 0.630
Double hit* 13/287 (5) 1/42 (2) 12/245 (5) 0.700
TP53 deletion 47/402 (12) 5/67 (7) 42/335 (13) 0.300
TP53 mutated 91/408 (22) 13/67 (19) 78/341 (23) 0.631
p53 expression 140/395 (36) 27/66 (41) 113/329 (34) 0.326
p50 expression 154/428 (36) 27/70 (39) 127/358 (35) 0.683
p52 expression 119/422 (28) 27/71 (38) 92/351 (26) 0.050
p65 expression 144/428 (34) 27/71 (38) 117/357 (33) 0.411
cRel expression 99/422 (24) 13/67 (19) 86/355 (24) 0.436
p50/p65 co-expression 77/422 (18) 14/70 (20) 63/352 (18) 0.735
p50/cRel co-expression 47/420 (11) 6/67 (9) 41/353 (12) 0.674
p52/p65 co-expression 41/414 (10) 11/70 (16) 30/344 (9) 0.081
p52/cRel co-expression 44/406 (11) 6/66 (9) 38/340 (11) 0.829
Classical NF-κB expression 100/427 (23) 15/70 (21) 85/357 (24) 0.758
Alternative NF-κB expression 71/417 (17) 12/70 (17) 59/347 (17) 1.000
NF-kB expression** 134/417 (32) 20/69 (29) 114/348 (33) 0.575
CD30 expression 72/439 (16) 12/72 (17) 60/367 (16) 1.000
pAKT expression 76/435 (17) 17/71 (24) 59/364 (16) 0.125
Cyclin D1 expression 10/432 (2) 2/71 (3) 8/361 (2) 0.672
pSTAT3, phosphorylated STAT3
*
double hit, MYC and BCL2 or BCL6 rearrangements
**
Summation of the classical and alternative NF-κB pathway expression
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